Microdosing GLP-1 means using semaglutide or tirzepatide at doses significantly below the standard therapeutic targets
While these three compounds are frequently searched together, they dont share a single mechanism each interacts with a different biological pathway, which is precisely why researchers often examine them side by side rather than as interchangeable options
Important monitoring includes: Blood sugar levels Regular glucose monitoring, especially for diabetes patients
Common adverse effects observed in clinical trials include nausea, vomiting, injection site reactions, increased heart rate, and hypoglycaemia risk
Tirzepatide is the first antidiabetic drug that is a dual agonist of both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
How It Works This injection contains Mecobalamin, an active form of Vitamin B12